FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034806119> ?p ?o ?g. }

• W2034806119 abstract "Following the successful introduction of oxaliplatin into the management of advanced colorectal cancer, its clinical utility is currently being investigated in a variety of other malignancies, including cancers of the upper gastrointestinal tract. In advanced pancreatic cancer, oxaliplatin has been found to be clinically effective in phase II trials in which it was combined with either 5-fluorouracil (5-FU) or gemcitabine, the current standard chemotherapy for this disease. In a phase II trial involving 67 patients, the combination of oxaliplatin and 5-FU in a high dose infusional regimen (n = 31) achieved an objective response rate of 9.7%, stable disease for at least three cycles in 48.4% of patients, tumour growth control in 58% of patients, a median time to progression of 4.9 months and median overall survival reaching 9.2 months. In combination with gemcitabine in a phase II trial involving 64 patients with metastatic (n = 34) or locally advanced (n = 30) pancreatic cancer, there was an objective response rate of 30.6%, treatment benefit in 39.7%, a median progression-free survival of 5.3 months and again a median overall survival of 9.2 months. Response rates and survival times did not differ between locally advanced and metastatic disease. On the basis of these encouraging results, phase III studies of oxaliplatin in advanced pancreatic cancer are now in progress in Europe and the United States. In metastatic gastric cancer, a phase II study investigated the combined use of oxaliplatin and 5-FU using the FOLFOX6 regimen in 53 patients, of whom 49 were evaluable for efficacy. The objective response rate was 44.9% and the median duration of response was 7.9 months. Large phase III trials of oxaliplatin-based treatment for advanced gastric cancer are now in progress. Oxaliplatin is also being investigated in oesophageal cancer and several other gastrointestinal tumours. In summary, oxaliplatin is emerging as an effective and highly promising chemotherapeutic agent for the treatment of upper gastrointestinal malignancies." @default.
• W2034806119 created "2016-06-24" @default.
• W2034806119 creator A5002926775 @default.
• W2034806119 creator A5036015683 @default.
• W2034806119 date "2003-10-30" @default.
• W2034806119 modified "2023-09-27" @default.
• W2034806119 title "The role of oxaliplatin in the management of upper gastrointestinal tract malignancies" @default.
• W2034806119 cites W1843791750 @default.
• W2034806119 cites W1848862702 @default.
• W2034806119 cites W1931508686 @default.
• W2034806119 cites W1977013624 @default.
• W2034806119 cites W1979177631 @default.
• W2034806119 cites W2007965665 @default.
• W2034806119 cites W2009003896 @default.
• W2034806119 cites W2016148872 @default.
• W2034806119 cites W2026986976 @default.
• W2034806119 cites W2035185002 @default.
• W2034806119 cites W2044313019 @default.
• W2034806119 cites W2045049074 @default.
• W2034806119 cites W2060878119 @default.
• W2034806119 cites W2061953534 @default.
• W2034806119 cites W2067437759 @default.
• W2034806119 cites W2082598176 @default.
• W2034806119 cites W2101310161 @default.
• W2034806119 cites W2121368761 @default.
• W2034806119 cites W2128889451 @default.
• W2034806119 cites W2135352785 @default.
• W2034806119 cites W2136664234 @default.
• W2034806119 cites W2144263487 @default.
• W2034806119 cites W2146266646 @default.
• W2034806119 cites W2313887201 @default.
• W2034806119 cites W2589845970 @default.
• W2034806119 cites W4230862377 @default.
• W2034806119 cites W4231089745 @default.
• W2034806119 cites W2033532635 @default.
• W2034806119 doi "https://doi.org/10.1046/j.1463-1318.5.s3.5.x" @default.
• W2034806119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23573559" @default.
• W2034806119 hasPublicationYear "2003" @default.
• W2034806119 type Work @default.
• W2034806119 sameAs 2034806119 @default.
• W2034806119 citedByCount "3" @default.
• W2034806119 countsByYear W20348061192015 @default.
• W2034806119 countsByYear W20348061192021 @default.
• W2034806119 crossrefType "journal-article" @default.
• W2034806119 hasAuthorship W2034806119A5002926775 @default.
• W2034806119 hasAuthorship W2034806119A5036015683 @default.
• W2034806119 hasConcept C121608353 @default.
• W2034806119 hasConcept C126322002 @default.
• W2034806119 hasConcept C143998085 @default.
• W2034806119 hasConcept C2776694085 @default.
• W2034806119 hasConcept C2777909004 @default.
• W2034806119 hasConcept C2780210213 @default.
• W2034806119 hasConcept C2780258809 @default.
• W2034806119 hasConcept C2780456651 @default.
• W2034806119 hasConcept C2780739268 @default.
• W2034806119 hasConcept C2780962732 @default.
• W2034806119 hasConcept C2781413609 @default.
• W2034806119 hasConcept C31760486 @default.
• W2034806119 hasConcept C526805850 @default.
• W2034806119 hasConcept C535046627 @default.
• W2034806119 hasConcept C71924100 @default.
• W2034806119 hasConcept C90924648 @default.
• W2034806119 hasConceptScore W2034806119C121608353 @default.
• W2034806119 hasConceptScore W2034806119C126322002 @default.
• W2034806119 hasConceptScore W2034806119C143998085 @default.
• W2034806119 hasConceptScore W2034806119C2776694085 @default.
• W2034806119 hasConceptScore W2034806119C2777909004 @default.
• W2034806119 hasConceptScore W2034806119C2780210213 @default.
• W2034806119 hasConceptScore W2034806119C2780258809 @default.
• W2034806119 hasConceptScore W2034806119C2780456651 @default.
• W2034806119 hasConceptScore W2034806119C2780739268 @default.
• W2034806119 hasConceptScore W2034806119C2780962732 @default.
• W2034806119 hasConceptScore W2034806119C2781413609 @default.
• W2034806119 hasConceptScore W2034806119C31760486 @default.
• W2034806119 hasConceptScore W2034806119C526805850 @default.
• W2034806119 hasConceptScore W2034806119C535046627 @default.
• W2034806119 hasConceptScore W2034806119C71924100 @default.
• W2034806119 hasConceptScore W2034806119C90924648 @default.
• W2034806119 hasLocation W20348061191 @default.
• W2034806119 hasLocation W20348061192 @default.
• W2034806119 hasOpenAccess W2034806119 @default.
• W2034806119 hasPrimaryLocation W20348061191 @default.
• W2034806119 hasRelatedWork W114118577 @default.
• W2034806119 hasRelatedWork W1988326884 @default.
• W2034806119 hasRelatedWork W2034806119 @default.
• W2034806119 hasRelatedWork W2037421249 @default.
• W2034806119 hasRelatedWork W2063123552 @default.
• W2034806119 hasRelatedWork W2067068996 @default.
• W2034806119 hasRelatedWork W2120848645 @default.
• W2034806119 hasRelatedWork W2518765238 @default.
• W2034806119 hasRelatedWork W2590528105 @default.
• W2034806119 hasRelatedWork W2941257841 @default.
• W2034806119 isParatext "false" @default.
• W2034806119 isRetracted "false" @default.
• W2034806119 magId "2034806119" @default.
• W2034806119 workType "article" @default.